FDA Approves First KRAS G12C Lung Cancer Drug

FDA just approved a groundbreaking new drug that targets a previously “undruggable” lung cancer mutation — KRAS G12C — offering real hope to patients who once had few options. This precision therapy blocks cancer growth in tumors with this rare genetic flaw, shrinking them in many patients and marking a major leap in personalized medicine. With a strong safety profile and promising trial results, it’s a game-changer for those with non-small cell lung cancer — and a reminder that genetic testing could be lifesaving. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/1f3ff036c5054f68